The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1-positive (PD-L1+) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051).
 
Birgit Geoerger
No Relationships to Disclose
 
Elizabeth Fox
Research Funding - GlaxoSmithKline; Merck
Travel, Accommodations, Expenses - GlaxoSmithKline
 
Alberto S. Pappo
Consulting or Advisory Role - ZIOPHARM Oncology
 
Michael Yalon Oren
No Relationships to Disclose
 
Lynley V Marshall
Honoraria - GlaxoSmithKline; Lilly
Consulting or Advisory Role - GlaxoSmithKline; Lilly
Travel, Accommodations, Expenses - Novartis; Roche/Genentech
 
Karl Heath
Employment - Merck
Stock and Other Ownership Interests - Nuvo Research
 
Scott J. Diede
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Scot Ebbinghaus
Employment - Merck
Stock and Other Ownership Interests - Merck
Patents, Royalties, Other Intellectual Property - Merck
 
Julie R. Park
Travel, Accommodations, Expenses - Roche